Valuation: HighTide Therapeutics, Inc.

Market Cap 1.3B 1.5B 192M 168M 155M 143M 269M 18.48B 274M 1.86B 728M 9.04B 720M 704M 31.15B P/E 2024
-1.41x
P/E 2025 -5.19x
Enterprise Value 922M 1.07B 136M 119M 110M 101M 191M 13.13B 194M 1.32B 517M 6.42B 511M 500M 22.13B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
44.17%
Yield 2024 *
-
Yield 2025 -
1 day+1.15%
Current month-1.87%
1 month-11.45%
3 months-31.51%
6 months-8.36%
Current year-10.85%
1 week 2.5
Extreme 2.5
3.01
1 month 2.32
Extreme 2.32
3.01
Current year 1.8
Extreme 1.8
4.72
1 year 1.8
Extreme 1.8
4.72
3 years 0.72
Extreme 0.72
13.18
5 years 0.72
Extreme 0.72
13.18
10 years 0.72
Extreme 0.72
13.18
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2011
Director of Finance/CFO 57 01/12/2022
Chief Tech/Sci/R&D Officer - 02/02/2026
Director TitleAgeSince
Director/Board Member 68 30/11/2020
Director/Board Member 61 -
Chairman 56 -
Date Insider Type Main position Quantity % Market Cap.
4/30/26 A Other

Director

1,800,000 0.3151%
4/1/26 A Other

Chief Executive Officer

8,325,618 1.4572%
4/1/25 A Other

Chief Executive Officer

3,960,550 0.7694%
Change 5-day change 1-year change 3-year change Capi.($)
+1.15%0.00%-27.15% - 189M
+0.21%-1.34%+53.17%+60.65% 53.83B
+5.37%+0.75%+50.39%+83.03% 52.1B
-1.20%-0.62%+5.53%+409.46% 23.48B
+0.74%+2.20%-15.48%-14.55% 23.13B
+3.46%+0.79%+34.01%-4.47% 19.36B
-1.18%-1.15%+30.12%-32.02% 17.56B
-1.67%-8.56%+163.95%+284.69% 15.2B
+3.62%-2.42%+29.70%+663.64% 14.83B
-0.70%+0.36%+27.07%+183.04% 14.06B
Average +1.25%+0.00%+35.13%+181.50% 23.37B
Weighted average by Cap. +1.70%-0.73%+41.73%+141.13%

Financials

2024 2025
Net sales - -
Net income -382M -442M -56.38M -49.42M -45.68M -42.01M -79.27M -5.44B -80.54M -546M -214M -2.66B -212M -207M -9.17B -245M -284M -36.18M -31.71M -29.31M -26.96M -50.86M -3.49B -51.68M -350M -137M -1.71B -136M -133M -5.88B
Net Debt -413M -478M -60.96M -53.43M -49.39M -45.42M -85.71M -5.88B -87.08M -591M -232M -2.88B -229M -224M -9.91B -376M -435M -55.52M -48.66M -44.98M -41.37M -78.06M -5.35B -79.31M -538M -211M -2.62B -208M -204M -9.03B
Logo HighTide Therapeutics, Inc.
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The Company has developed a product pipeline of multiple product candidates in-house, covering many indications in metabolic and digestive diseases among which, some are at clinical-stage. The Company’s core product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases. The Company conducts operations in the United States, Mainland China, Hong Kong and Australia.
Employees
51
Date Price Change Volume
20/07/26 HK$2.630 +1.15% 123,000
17/07/26 HK$2.600 -5.45% 178,500
16/07/26 HK$2.750 +5.36% 218,000
15/07/26 HK$2.610 +2.35% 121,000
14/07/26 HK$2.550 -0.39% 164,000

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2511 Stock